The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer

Официальное название

The Addictive Diagnostic Value of Apparent Diffusion Coefficients to PI-RADS 3-5 of Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer

Обзор

The goal of this study is to evaluate the diagnostic value of different ADC values (incuding ADCmin, ADCmean, ADCratio and ADCrange) of bpMRI in patients with PI-RADS 3-5. The main aim is to evaluate whether different ADC values improve the diagnosis of clinically significant prostate cancer (Gleasonscore≥3+4, ISUP grade ≥2) and any-grade prostate cancer (Gleasonscore≥3+3, ISUP grade ≥1).

Подробное описание

The study is conducted with suspected prostate cancer. Patients with PI-RADS scores of 3-5 after completing prostate bpMRI chose to undergo prostate biopsy. Before patients undergo prostate biopsy, researchers will collecte information on age, BMI, tPSA, f/PSA, PV, PSAD, ADCmean, ADCmin, ADCmax, ADCnormal, maximum lesion diameter, location of major lesions, and so on. For prostate biopsy, systematic prostate biopsy ± bpMRI cognitive fusion targeted prostate biopsy will be completed under the conditions permitted by physical condition, and Gleason score will be clearly given by pathologists if the final diagnosis is prostate cancer. In this study, the pathological result is regarded as the gold standard. ROC curve, area under curve, sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio and other indicators of diagnostic test were calculated. Relevant conclusions are finally drawn by comparing the diagnostic capacity of different ADC values for prostate cancer. Meanwhile, binary logistic regression analysis will also conduct the Odds ratios (ORs) and 95% confidence intervals (CIs) will be recorded.

Первичные конечные точки

• Evaluate whether ADC values can improve the diagnostic capacity of bpMRI for clinically significant prostate cancer (csPCa) (Gleason score ≥ 3+4, ISUP grade ≥ 2) in patients with PI-RADS 3-5. [Срок оценки: through study completion, an average of 1 month]

Вторичные конечные точки (3)

• Evaluate whether ADC values can improve the diagnostic capacity of bpMRI for any-grade prostate cancer (PCa) (Gleason score ≥ 3+3, ISUP grade ≥ 1) in patients with PI-RADS 3-5. [Срок оценки: through study completion, an average of 1 month]
• Evaluate the diagnostic capacity of different PI-RADS scores combined with different ADC cut off values for csPCa [Срок оценки: through study completion, an average of 1 month]
• Compare the diagnostic value of different ADC values for csPCa in patients with 3-5 points of PI-RADS. [Срок оценки: through study completion, an average of 1 month]

Критерии участия

Критерии включения

• The patient met at least one indication of prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) https://rs.yiigle.com/cmaid/1442948 );
• Serum PSA test was completed in the patient with tPSA < 100 ng/ml;
• Primary prostate tumor lesion, no history of other tumors;
• Completed 3.0T bpMRI examination, PI-RADS score ≥3 score, the image is clear and readable;
• Patients fully understand the relevant contents of the study and voluntarily sign the informed consent.

Критерии исключения

• The patient has contraindications for MRI;
• PI-RADS 1-2 of bpMRI;
• The patient had contraindications to prostate biopsy or explicitly refused biopsy;
• bpMRI indicated that the patient had multiple lymph nodes or bone metastases;
• Previous prostate-related surgery;
• The patient refused to sign the informed consent.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Другое

Центры проведения

Китай · 2 центра

• Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences an — Хэфэй
• Department of Urology, The First Affiliated Hospital of Wannan Medical College — Wuhu

Идентификаторы

NCT: NCT06737588 · 2024-ky-495 (bpMRI-ADC)

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗